Approach to lipoprotein management in 2001 National Cholesterol guidelines

American Journal of Cardiology

Volumn 90, Issue 8 SUPPL., 2002, Pages 11-21

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; SIMVASTATIN; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIET THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; DYSPEPSIA; EDUCATION PROGRAM; FLUSHING; GALLSTONE; GASTROINTESTINAL SYMPTOM; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERURICEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LIVER TOXICITY; MEDICAL RESEARCH; METABOLIC DISORDER; METABOLIC SYNDROME X; MYOPATHY; PATHOGENESIS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0037126372     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02631-0     Document Type: Article

References (71)

1. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2508-2509.
2. Expert Panel . Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults, National Heart, Lung, and Blood Institute. Arch Intern Med. 148:1988;36-69.
3. Lipid Research Clinics Program . The Lipid Research Clinics coronary primary prevention trial results I. reduction in the incidence of coronary heart disease . JAMA. 251:1984;351-364.
4. Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention Trial Results II. the relationship of reduction in incidence of coronary heart disease to cholesterol lowering . JAMA. 251:1984;365-374.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel II). Circulation. 89:1994;1333-1445.
6. Rossouw J.E., Lewis B., Rifkind B.M. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 323:1990;1112-1119.
7. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 319:1988;24-33.
8. Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
9. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.-C., Davis B.R., Braunwald E., for the Cholesterol and Recurrent Events Trial Investigators . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
10. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
11. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J., for the West of Scotland Coronary Prevention Study Group . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
12. Downs J.R., Clearfield M., Whitney E., Shapiro D., Beere P.A., Gotto A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
13. Miller B.D., Alderman E.L., Haskell W.L., Fair J.M., Krauss R.M. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation. 94:1996;2146-2153.
14. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., Sacks F.M., Hennekens C.H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:1996;882-888.
15. Gardner C.D., Fortmann S.P., Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 276:1996;875-881.
16. Lamarche B., Lemieux I., Despres J.P. The small, dense LDL phenotype and the risk of coronary heart disease epidemiology, patho-physiology and therapeutic aspects . Diabetes Metab. 25:1999;199-211.
17. Austin M.A. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep. 2:2000;200-207.
18. Kral B.G., Becker L.C., Yook R.M., Blumenthal R.S., Kwiterovich P.O. Jr, Otvos J.D., Becker D.M. Racial differences in low-density lipoprotein particle size in families at high risk for premature coronary heart disease. Ethn Dis. 11:2001;325-337.
19. St-Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., Bernard P.M., Despres J.I., Lamarche B. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 104:2001;2295-2299.
20. Tribble D.L., Rizzo M., Chait A., Lewis D.M., Blanche P.J., Krauss R.M. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med. 110:2001;103-110.
21. Otvos J.D., Jeyarajah E.J., Bennett D.W. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem. 37:1991;377-386.
22. Otvos J.D., Jeyarajah E.J., Bennett D.W., Krauss R.M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 38:1992;1632-1638.
23. Freedman D.S., Otvos J.D., Jeyarajah E.J., Barboriak J.J., Anderson A.J., Walker J.A. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 18:1998;1046-1053.
24. Havel R.J. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol. 11:2000;615-620.
25. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W., Ordov J.M., Schaefer E.J. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women results from the Framingham Heart Study . Atherosclerosis. 154:2001;229-236.
26. Marcoux C., Tremblay M., Fredenrich A., Davignon J., Cohn J.S. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Metabolism. 50:2001;112-119.
27. Schreuder P.C., Twickler T.B., Wang T., Nakajima K., Erkelens D.W., Dallinga-Thie G.M. Isolation of remnant particles by immunoseparation a new approach for investigation of postprandial lipoprotein metabolism in normolipidemic subjects . Atherosclerosis. 157:2001;145-150.
28. Sniderman A.D., Wolfson C., Teng B., Franklin F.A., Bachorik P.S., Kwiterovich P.O. Jr. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med. 97:1982;833-839.
29. Stein E.A. Lipid risk factors and atherosclerosis what do we measure? Scand J Clin Lab Invest. 198:(suppl):1990;3-8.
30. Kwiterovich P.O. Jr, Coresh J., Smith H.H., Bachorik P.S., Derby C.A., Pearson T.A. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol. 69:1992;1015-1021.
31. Sniderman A.D. The measurement of apolipoprotein B should replace the conventional lipid profile in screening for cardiovascular risk. Can J Cardiol. 8:1992;133-138.
32. Lamarche B., Moorjani S., Lupien P.J., Cantin B., Bernard P.M., Dagenais G.R., Despres J.P. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 94:1996;273-278.
33. Sniderman A.D. Counterpointto (measure apo) B or not to (measure apo) B a critique of modern medical decision-making . Clin Chem. 43:1997;1310-1314.
34. Sniderman A.D. Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease. Can J Cardiol. 4:(suppl A):1988;24A-30A.
35. Westerveld H.T., van Lennep J.E., van Lennep H.W., Liem A.H., de Boo J.A., van der Schouw Y.T., Erkelens D.W. Apolipoprotein B and coronary artery disease in women a cross-sectional study in women undergoing their first coronary angiography . Arterioscler Thromb Vasc Biol. 18:1998;1101-1107.
36. Shechter M., Bairey Merz C.N., Paul-Labrador M.J., Shah P.K., Kaul S. Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease. Cardiology. 92:1999;151-155.
37. Sniderman A.D., Bergeron J., Frohlich J. Apolipoprotein B versus lipoprotein lipids vital lessons from the AFCAPS/TexCAPS trial . CMAJ. 164:2001;44-47.
38. Sniderman A.D., Dagenais G.R., Cantin B., Despres J.P., Lamarche B. High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol. Am J Cardiol. 87:2001;792-793.
39. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) a prospective study . Lancet. 358:2001;2026-2033.
40. Vega G.L., Grundy S.M. Does measurement of apolipoprotein B have a place in cholesterol management? Arteriosclerosis. 10:1990;668-671.
41. Abate N., Vega G.L., Grundy S.M. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 104:1993;159-171.
42. Frost P.H., Havel R.J. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol. 81:1998;26B-31B.
43. Grundy S.M. Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. Arch Intern Med. 161:2001;1379-1380.
44. Gardner C.D., Winkleby M.A., Fortmann S.P. Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988-1994). Am J Cardiol. 86:2000;299-304.
45. Cui Y., Blumenthal R.S., Flaws J.A., Whiteman M.K., Langenberg P., Bachorik P.S., Bush T.L. Non-high density lipoprotein cholesterol as a predictor of cardiovascular disease mortality. Arch Intern Med. 161:2001;1413-1419.
46. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C., ACCESS Study Group . Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels . Am J Cardiol. 88:2001;265-269.
47. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Survey. JAMA. 287:2002;356-359.
48. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 104:2001;365-372.
49. Grundy S.M., Wilhelmsen L., Rose G., Campbell R.W.F., Assman G. Coronary heart disease in high-risk populations lessons from Finland . Eur Heart J. 11:1990;462-471.
50. Fuster V. Understanding the coronary disease process and the potential for prevention a summary . Prev Med. 29:1999;S9-S10.
51. Brown B.G., Zhao X.-Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression new insights into prevention of plaque disruption and clinical events in coronary disease . Circulation. 87:1993;1781-1791.
52. Wilson P.W.F., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847.
53. National Institutes of Health . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res. 2:1998;51S-209S.
54. Smith S.C. Jr, Greenland P., Grundy S.M. AHA Conference Proceedings. Prevention Conference V beyond secondary prevention. Identifying the high-risk patient for primary preventionexecutive summary. American Heart Association . Circulation. 101:2000;111-116.
55. Greenland P., Smith S.C. Jr, Grundy S.M. Improving coronary heart disease risk assessment in asymptomatic people role of traditional risk factors and noninvasive cardiovascular tests . Circulation. 104:2001;1863-1867.
56. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., Gotto A.M. Jr, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators . Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:2001;1959-1965.
57. Smith D., Shipley M.J., Batty G.D., Morris J.N., Marmot M. Physical activity and cause-specific mortality in the Whitehall study. Public Health. 114:2000;308-315.
58. Wannamethee S.G., Shaper A.G. Physical activity in the prevention of cardiovascular disease an epidemiological perspective . Sports Med. 31:2001;101-114.
59. Gueyffier F., Froment A., Gouton M. New meta-analysis of treatment trials of hypertension improving the estimate of therapeutic benefit . J Hum Hypertens. 10:1996;1-8.
60. Gueyffier F., Boutitie F., Boissel J.P., Pocock S., Coope J., Cutler J., Ekbom, Fagard R, Friedman L., Perry M., Prineas R., Schron E. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDIANA Investigators. Ann Intern Med. 126:1997;761-767.
61. Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 324:2002;71-86.
62. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
63. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:2001;1933-1935.
64. Devaraj S., Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radic Biol Med. 29:2000;790-792.
65. Johansson J.O., Egberg N., Asplund-Carlson A., Carlson L.A. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men. J Cardiovasc Risk. 4:1997;165-171.
66. de Maat M.P., Knipscheer H.C., Kastelein J.J., Kluft C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. Thromb Haemost. 77:1997;75-79.
67. Fruchart J.C., Duriez P., Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 10:1999;245-257.
68. Grundy S.M., Vega G.L., McGovern M.E. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial (ADVENT). Arch Intern Med. 162:2002;1568-1576.
69. Kashyap M.L., McGovern M.E., Berra K. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 89:2002;672-678.
70. Heart Protection Study Collaborative Group . MRC/BHF heart protection study Randomised placebo-controlled trial of cholesterol-lowering with simvastatin in 20,536 high-risk individuals . Lancet. 360:2002;7-22.
71. Collins-Nakai R.L., Dagenais G.R,. The role of cardiovascular specialist in the prevention of cardiovascular diseases-executive summary. Can J Cardiol. 15:(Suppl G):1999;7G-16G.